Demis Hassabis, cofounder of DeepMind and 2024 Nobel Laureate, talks to Fortune about his AI drug discovery startup, ...

Though Isomorphic is burning through millions in R&D costs now, investors have high hopes for the potential of AI drug ...

Google’s artificial intelligence arm DeepMind has been holding back the release of its world-renowned research, as it seeks ...

Isomorphic Labs was founded to apply artificial intelligence to drug discovery. The company is led by AI researcher Sir Demis Hassabis.

Isomorphic Labs says it is advancing drug design programs across multiple therapeutic areas and drug modalities. These ...

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital ...

Isomorphic Labs, which uses artificial intelligence technologies for drug discovery, has raised $600 million in its first ...

AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict ...

The drug discovery company, which has partnerships with Eli Lilly and Novartis, is developing AI models to design drugs and ...

The London-based business – which launched in 2021 – will use the funds to further its research, expand its team and continue ...

The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital ...

The funding is set to accelerate the development of Isomorphic’s AI drug design engine and advance clinical programmes.